|
Trial title | Objectives | Study type | Source | Trial number |
|
Micro-RNA Expression Profiles in High Risk Prostate Cancer | Correlation of miRNA expression with prostate cancer outcome | Observational retrospective | Radical prostatectomy | NCT01220427
a |
|
Blood and Tissue Samples From Patients with Locally Recurrent or Metastatic Prostate Cancer | Sequencing of genomic tumor DNA, genotyping, gene expression, and miRNA/noncoding RNA | Observational prospective | Blood, soft tissue or bone metastases | NCT01050504
a |
|
MicroRNA in Prostate Cancer Progression: Genetic Variation, Genotype-Phenotype Correlation, and Circulating Biomarker | MiRNAs as predictors of progression | Biomarker screening | Tumor versus normal tissue, plasma | MD Anderson Cancer Centerb |
|
Abiraterone Acetate in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer | MiRNA expression in tumor metastases as biomarker for sensitivity and resistance; correlation of miRNA with response and progression | Interventional, Phase II clinical trial | Blood (biopsy) | NCT01503229
a |
|
Bicalutamide and Goserelin or Leuprolide Acetate w/wo Cixutumumab in Patients with Newly Diagnosed Metastatic Prostate Cancer | Correlation of miRNA expression and CTC count | Interventional, Phase II clinical trial | Serum | NCT01120236
a |
| | | | |
|